Ningxia Zhongke Biotechnology Co., Ltd.
600165.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.19 | -0.03 | -0.06 | 1.26 |
| FCF Yield | -5.49% | -1.47% | -0.13% | -2.81% |
| EV / EBITDA | -6.15 | -12.23 | 112.84 | -74.38 |
| Quality | ||||
| ROIC | -112.51% | -33.01% | -1.09% | 0.09% |
| Gross Margin | -19.54% | -47.12% | 11.11% | 12.42% |
| Cash Conversion Ratio | 0.15 | -0.05 | -0.31 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -20.26% | 14.09% | 78.82% | -10.21% |
| Free Cash Flow Growth | -164.69% | -460.02% | 97.61% | 66.62% |
| Safety | ||||
| Net Debt / EBITDA | -0.72 | -2.27 | 18.28 | -5.99 |
| Interest Coverage | -3.85 | -3.47 | -0.24 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 4.05 | 4.39 | 5.54 | 1.72 |
| Cash Conversion Cycle | -555.68 | -391.67 | -331.33 | -924.10 |